istock-508496956cosmin4000

cosmin4000 / iStockphoto.com

27 September 2018Americas

IP and personalised medicine: a tailor-made approach

In 2017, the US Food and Drug Administration (FDA) approved a record 16 new personalised medicines, according to the “Personalized Medicine at FDA: 2017 Progress Report”. From 2014 to 2017, more than one in every four drugs the agency approved was a personalised medicine.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

LSIPR 50 2018: Personalised medicine: the way forward

13 July 2018 BMS’s teams are working to answer key questions and more intimately understand the interplay between the immune system and cancer, Paul Golian, vice president and assistant counsel of IP at BMS, tells LSIPR.

article

Personalised medicine in Europe: is the patent system keeping up?

19 February 2014 The rise of so-called personalised medicine presents new challenges and opportunities for drugs companies, says Robert Andrews.

More on this story

LSIPR 50 2018: Personalised medicine: the way forward

13 July 2018 BMS’s teams are working to answer key questions and more intimately understand the interplay between the immune system and cancer, Paul Golian, vice president and assistant counsel of IP at BMS, tells LSIPR.

article

Personalised medicine in Europe: is the patent system keeping up?

19 February 2014 The rise of so-called personalised medicine presents new challenges and opportunities for drugs companies, says Robert Andrews.

More on this story

LSIPR 50 2018: Personalised medicine: the way forward

13 July 2018 BMS’s teams are working to answer key questions and more intimately understand the interplay between the immune system and cancer, Paul Golian, vice president and assistant counsel of IP at BMS, tells LSIPR.

article

Personalised medicine in Europe: is the patent system keeping up?

19 February 2014 The rise of so-called personalised medicine presents new challenges and opportunities for drugs companies, says Robert Andrews.

More features

Fed Circ orders Teva to delist five patents from Orange Book

Sarepta wins $115M in patent dispute over muscular dystrophy drug

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York